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Introduction
The major regulatory pathways promoting induction of autoph-
agy converge on the covalent lipidation of LC3 (microtubule- 
associated protein 1 light chain 3). Like its yeast homologue 
Atg8, LC3 is cleaved to liberate a C-terminal glycine needed for 
its conjugation to phospholipids upon autophagy induction. This 
processing and recruitment is essential for extension, curvature, 
and closure of the isolation membrane to form autophagosomes 
(He and Klionsky, 2009), also playing a role in cargo recogni-
tion (Pankiv et al., 2007). Lipidated LC3 is a useful marker of 
autophagic membranes, as it migrates to an apparently lower Mr 
position (LC3-II) by electrophoresis, and autophagosomes are 
visualized as bright GFP-LC3 puncta (Klionsky et al., 2008). 
Although much has been learned about the processing of LC3 
necessary to initiate autophagy, regulatory mechanisms capable 
of modulating or fine tuning its participation in autophagy re-
main poorly understood.
It is recognized that a fine balance of stress-induced autoph-
agy is important (Cuervo, 2004), particularly in neuronal cells 
(Boland and Nixon, 2006; Jaeger and Wyss-Coray, 2009), as 
autophagy functions to reduce protein aggregates but can also 
contribute to neurite degeneration (Yang et al., 2007; Plowey   
et al., 2008). Indeed, a current translational challenge is to harness   
beneficial effects of autophagy without eliciting harm (Zhang et al., 
2007). We have previously shown that treatment with dibutyryl-
cAMP (db-cAMP) protects against parkinsonian neurotoxins 
(Chalovich et al., 2006). Because PKA signaling can regulate au-
tophagy in other cell types (Holen et al., 1996; Budovskaya et al.,   
2004), we investigated whether PKA regulation of autophagy 
protected against parkinsonian neurodegeneration.
M
acroautophagy is a major catabolic pathway 
that impacts cell survival, differentiation, tumori­
genesis,  and  neurodegeneration.  Although 
bulk degradation sustains carbon sources during starva­
tion, autophagy contributes to shrinkage of differentiated 
neuronal  processes.  Identification  of  autophagy­related 
genes  has  spurred  rapid  advances  in  understanding 
the recruitment of microtubule­associated protein 1 light 
chain 3 (LC3) in autophagy induction, although braking 
mechanisms remain less understood. Using mass spec­
trometry, we identified a direct protein kinase A (PKA) 
phosphorylation site on LC3 that regulates its participation 
in autophagy. Both metabolic (rapamycin) and pathological 
(MPP
+)  inducers  of  autophagy  caused  dephosphoryla­
tion of endogenous LC3. The pseudophosphorylated LC3 
mutant showed reduced recruitment to autophagosomes, 
whereas the nonphosphorylatable mutant exhibited en­
hanced puncta formation. Finally, autophagy­dependent 
neurite shortening induced by expression of a Parkinson 
disease–associated  G2019S  mutation  in  leucine­rich   
repeat kinase 2 was inhibited by dibutyryl–cyclic adeno­
sine monophosphate, cytoplasmic expression of the PKA 
catalytic subunit, or the LC3 phosphorylation mimic. These 
data demonstrate a role for phosphorylation in regulating 
LC3 activity.
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neuronal cells. Treatment with db-cAMP reduced the number of 
autophagic vacuoles (AVs) induced by either LRRK2 G2019S 
or MPP
+ (Fig. 1, e, h, and i).
To determine whether db-cAMP reduced GFP-LC3 puncta 
by decreasing autophagy induction or by increasing AV matura-
tion, we treated cells with rapamycin to induce autophagy and 
used the tandem reporter RFP-GFP-LC3 (Kimura et al., 2007), 
which labels early AVs with dual red and green fluorescence 
and late AVs with red only (Fig. 2 a). Rapamycin increased the 
number of early AVs at 1 h (Fig. S1 c). At 3 h, there was an 
increase in both early and late AVs (Fig. 2, b and c), which is 
consistent with maturation of rapamycin-induced AVs. Cotreat-
ment with db-cAMP reduced the number of rapamycin-induced 
AVs at all time points (Fig. 2, a–c; and Fig. S1 c). Because 
db-cAMP reduced the number of rapamycin-induced early AVs 
without increasing late AVs, these data suggest that cAMP/PKA 
signaling suppresses autophagy induction. Treatment with the 
PKA inhibitor (E)-N-(2-(3-(4-bromophenyl)allylamino)ethyl)-
isoquinoline-5-sulfonamide (H89) led to an increase in lipidated 
Results and discussion
Neuritic/synaptic dysfunction or degeneration are observed in 
clinical studies of Parkinson disease (PD) patients and in genetic 
and toxic/environmental models of PD. For example, expression 
of the autosomal dominant PD-associated G2019S mutant form   
of LRRK2 (leucine-rich repeat kinase 2) causes shortening of 
neurite lengths and simplification of branch points as indices   
of neuritic injury (MacLeod et al., 2006; Plowey et al., 2008).   
In this study, we observed that treatment with db-cAMP or co-
expression of a GFP-tagged PKA catalytic subunit prevented neu-
rite injury caused by LRRK2 G2019S in cortical neurons (Fig. 1,   
a–c). As  previously  observed  with  LRRK2  (MacLeod  et al., 
2006), there were no effects on the mean soma area (Fig. 1 d).   
db-cAMP also protected against neuronal injury caused by LRRK2 
G2019S and the parkinsonian neurotoxin MPP
+ in differentiated 
SH-SY5Y cells (Fig. 1, e–g). Because both injuries are mediated 
by autophagy (Fig. S1 a; Zhu et al., 2007; Plowey et al., 2008), 
we investigated whether PKA activity regulated autophagy in 
Figure 1.  PKA signaling reduces neurite in­
jury  and  autophagy.  (a–d)  Mouse  cortical   
neurons  coexpressing  GFP  or  GFP-PKA  and 
LRRK2 G2019S or vector 7 d after transfection.   
(b)  Quantification  of  neurite  lengths.  *,  P  = 
0.001  versus  empty  vector/GFP;  **,  P  = 
0.007 versus LRRK2 G2019S/GFP (n = 50–60 
cells/condition). (c) Quantification of branch 
points. *, P = 0.001 versus empty vector/GFP; 
**,  P  =  0.015  versus  LRRK2  G2019S/GFP   
(n  =  50–60  cells/condition).  (d)  Quantifica-
tion of soma area (n = 50–60 cells/condition).   
(e,  f,  and  h)  SH-SY5Y  neurites  expressing 
GFP-LC3 48 h after transfection with/without 
cAMP for 24 h. (f) Quantification of neurite 
lengths. *, P = 1.48 × 10
5 versus empty vec-
tor/vehicle; **, P = 9.21 × 10
5 versus LRRK2 
G2019S/vehicle (n = 80–90 cells/condition). 
(g) Quantification of neurite lengths from MPP
+-
treated SH-SY5Y cells with/without cAMP for 
48 h. *, P = 0.0298 versus control/vehicle; 
**,  P  =  0.0166  versus  MPP
+/vehicle  (n  =   
50–60 cells/condition). (h) Quantification of   
GFP-LC3–labeled puncta with/without cAMP for   
24 h. *, P = 0.006 versus empty vector/vehicle; 
**, P = 6.58 × 10
4 versus LRRK2 G2019S/
vehicle (n = 80–90 cells/condition). (i) Quan-
tification of GFP-LC3 puncta from MPP
+-treated 
SH-SY5Y  cells  with/without  cAMP.  *,  P  = 
6.06 × 10
4 versus control/vehicle; **, P = 
0.004 versus MPP
+/vehicle (n = 50–55 cells/
condition). Error bars indicate mean ± SEM.   
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more acidic isoelectric points, which is consistent with increased 
phosphorylation (Fig. 3 a). In living cells, we found that forskolin   
elicited increased 
32P incorporation into HA-tagged LC3 (Fig. 3 b), 
which was prevented by cotreatment with the PKA inhibitor 
H89 (Fig. 3 b). Using in vitro kinase assays, we determined that 
PKA was capable of directly phosphorylating recombinant rat 
LC3 (Fig. 3 c).
We  used  matrix-assisted  laser  desorption/ionization 
(MALDI) time of flight (TOF) mass spectrometry (MS) to iden-
tify the PKA phosphorylation site on LC3. Analysis of the MS1 
spectra revealed a singly charged peptide [M
+H]
+ ion signal at 
m/z 821.33 (Fig. 3 d) that was lost from samples treated with 
PKA, accompanied by the appearance of a new peptide [M
+H]
+ 
ion signal at m/z 901.41, corresponding to the predicted 80 D 
gain of a phosphate group (Fig. 3 e). Alkaline phosphatase treat-
ment of PKA-phosphorylated LC3 eliminated the ion signal at 
m/z 901.41 (unpublished data). Tandem MS/MS analysis identi-
fied the m/z 901.41 ion as residues 8–13 containing a phosphory-
lation at serine 12 (Fig. S2 a). To confirm that serine 12 was the 
PKA phosphorylation site, mutagenesis of serine 12 to alanine 
(S12A) abolished LC3 phosphorylation by PKA (Fig. 3 f). Custom 
antibodies generated to the phosphorylated peptides effectively 
labeled PKA-phosphorylated recombinant LC3 (Fig. S2 b) and 
endogenously phosphorylated LC3 in SH-SY5Y and cortical   
LC3-II  in  SH-SY5Y,  HeLa,  and  293T  cells  (Fig.  2  d  and   
Fig. S1 b), further indicating that PKA down-regulates autoph-
agy induction.
Because PKA has both transcriptional (Chalovich et al., 
2006) and posttranslational (Bok et al., 2003) neuroprotective 
effects, we used untargeted, nuclear-targeted (NLS), or cytoplasmic- 
targeted (nuclear export signal) GFP-tagged PKA (Bok et al., 
2003) to study the effects of PKA subcellular localization on au-
tophagy. Although the targeted PKA constructs elicited similar 
levels of cAMP response element binding protein phosphoryla-
tion (not depicted), nuclear localized PKA was unable to sig-
nificantly reduce the number of AVs induced by rapamycin or 
LRRK2 G2019S (Fig. 2, e and f), whereas nuclear excluded 
PKA showed the same potency as untargeted PKA. These results 
suggest that the effect of PKA on autophagy is mediated by a 
cytoplasmic target.
To identify potential autophagy-modulating cytoplasmic 
targets of PKA, we performed isoelectric focusing/SDS-PAGE 
2D gel analysis on untreated cortical neurons (Fig. 3 a) and   
SH-SY5Y cells (not depicted). 2D immunoblots for LC3 re-
vealed the presence of distinct species differing in isoelectric 
points, which is consistent with multiple phosphorylation states. 
Furthermore, treatment with forskolin, a known regulator of 
adenylate cyclase, increased the intensity of species migrating at 
Figure 2.  Cytoplasmic PKA inhibits autophagy. (a) RFP-GFP-LC3–labeled AVs in SH-SY5Y cells treated with rapamycin ± cAMP for 1 h. (b) Quantification 
of early AVs (GFP
+ RFP
+ puncta) in SH-SY5Y cells cotreated with rapamycin and cAMP for 3 h. *, P = 2.65 × 10
6 versus vehicle lacking rapamycin;   
**, P = 0.001 versus vehicle with rapamycin (n = 45–50 cells/condition). (c) Quantification of late AVs (RFP
+-only puncta) in SH-SY5Y cells cotreated with 
rapamycin and cAMP for 3 h. *, P < 0.008 versus vehicle without rapamycin; **, P < 0.05 versus vehicle with rapamycin (n = 50–55 cells/condition). 
(d) LC3 immunoblot of SH-SY5Y cells treated with H89 or vehicle for 1 h. (e) Quantification of endogenous LC3-immunolabeled AVs in SH-SY5Y cells after 
1-h treatment with rapamycin or DMSO (vehicle). *, P = 0.003 versus vehicle/GFP; **, P < 0.013 versus rapamycin/GFP (n = 35–45 cells/condition).   
(f) Quantification of endogenous LC3-immunolabeled AVs in SH-SY5Y cells 48 h after transfection. *, P = 3.52 × 10
4 versus empty vector/GFP group;   
**, P < 4.66 × 10
5 versus LRRK2 G2019S/GFP group (n = 80–90 cells/condition). Error bars indicate mean ± SEM. Bars, 20 µm.JCB • VOLUME 190 • NUMBER 4 • 2010   536
number of GFP-LC3–positive AVs, we transfected cells with a 
nonphosphorylatable mutant, GFP-LC3–S12A. Under basal con-
ditions, GFP-LC3–S12A migrated predominantly as a lipidated 
LC3-II band, forming more puncta than GFP-LC3–wild type (WT; 
Fig. 4, c and d), indicating that phosphorylation of LC3 regulates 
its incorporation into AVs.
We determined whether dephosphorylation contributed to   
autophagy induction using the S12D phosphomimetic mutant   
in cells treated with rapamycin. The S12D mutation reduced   
the number of GFP-LC3 puncta in rapamycin-treated cells (Fig. 5,   
a and b). Similarly, the S12D mutant formed significantly fewer 
puncta in cells expressing LRRK2 G2019S or in cells treated 
with MPP
+ (Fig. 5, c and d). Furthermore, the autophagy- 
related neurite shortening caused by LRRK2 G2019S or MPP
+ 
was attenuated by the S12D mutation in SH-SY5Y cells and 
cortical neurons (Fig. 5, e–h). Collectively, the data indicate that 
LC3 phosphorylation by PKA suppresses induced autophagy and 
neurons but not in the presence of the immunizing peptide   
(Fig. S2 c). Endogenously phosphorylated LC3 was further in-
creased by treatment with forskolin to stimulate PKA (Fig. 3 g).
We  investigated  whether  endogenous  LC3  phosphoryla-
tion was regulated by rapamycin or MPP
+, two stimuli that in-
duce increased autophagic flux (Budovskaya et al., 2005; Zhu 
et al., 2007). Treatment with either rapamycin or MPP
+ led to 
a reduction in phospho-LC3 as compared with vehicle-treated 
cells (Fig. 4, a and b) with no significant change in levels of LC3 
probed using an antibody raised against a C-terminal region epi-
tope of mature LC3 distant to the phosphorylation site (LC3). 
These results suggest that LC3 is dephosphorylated during au-
tophagy induction. Blots reprobed using the N-terminal antibody 
for LC3 revealed the expected increase in LC3-II caused by   
rapamycin. Endogenously phosphorylated LC3 comigrated with 
nonlipidated forms of LC3 (Fig. 3 g and Fig. S2 c). To determine 
whether loss of phosphorylation was sufficient to increase the 
Figure 3.  PKA directly phosphorylates LC3. (a) 2D immunoblot probed for LC3 shows distinct species differing by isoelectric points. Forskolin increases 
abundance of species with a more acidic isoelectric point. (b) Metabolic labeling reveals greater 
32P incorporation in HA-LC3 immunoprecipitated from 
forskolin-treated cells compared with control cells. Error bars indicate mean ± SEM. *, P < 0.05 versus vehicle; **, P < 0.05 versus forskolin (n = 3 inde-
pendent experiments). (c) In vitro kinase assay with recombinant PKA and purified rat LC3. Phosphorylation was detected by autoradiography. Coomassie 
stain shows migration of the recombinant proteins. (d and e) Recombinant LC3 was incubated with ATP in the presence and absence of PKA. In the presence 
of PKA and ATP, the m/z 821.33 ion is lost with the appearance of an m/z 901.41 ion. (f) Mutation of the LC3 phosphorylation site to S12A abolishes 
PKA phosphorylation of LC3. (g) Immunoblot of cortical neurons treated with forskolin or DMSO (vehicle) probed with phospho-specific LC3 antibody, total 
LC3 antibody (LC3-nt), and lamin antibody as a loading control.537 PKA regulation of LC3 • Cherra et al.
structure has not been identified in mammals, phosphoryla-
tion of LC3 reduces its recruitment to rapamycin or MPP
+-
induced autophagosomes.
Interestingly,  yeast  and  Drosophila  melanogaster  Atg8 
lack this particular PKA consensus site, although it is conserved 
in all mammalian forms of LC3 (Fig. S3) but not in the other 
mammalian Atg8 homologues, GABARAP and GATE16. The 
crystal structures of LC3, GABARAP, and GATE16 demonstrate 
significant charge differences in the N-terminal helices, which 
underlie the differences in their biological functions (Sugawara 
et al., 2004). Phosphorylation-related decreases in the net-positive 
charge of the LC3 N-terminal region may affect its interactions 
with phospholipids, proteins involved in target recognition, lipi-
dation (Yamada et al., 2007), cytoskeleton, or other functions 
(Kouno et al., 2005; Wang et al., 2006).
Although  PKA  is  a  major  nutrient-sensing  pathway  in 
yeast, it plays additional important roles in the mammalian ner-
vous system. Among these is the ability of PKA to promote neu-
ronal differentiation and neurite outgrowth, which has been 
predominantly  studied  in  terms  of  transcriptional  regulation. 
However, recent studies indicate that autophagy plays a direct 
role in mediating neurite retraction in neurons subjected to tro-
phic factor withdrawal, physical axotomy, or toxicity because of 
chemical or genetic factors (Yang et al., 2007; Plowey et al., 
2008). As neurite extension/retraction likely reflects a balance of 
biosynthetic and degradative processes, the ability of cytoplas-
mically expressed PKA catalytic subunit to phosphorylate LC3 
and suppress autophagy-dependent neurite retraction represents 
a novel mechanism contributing to effects of PKA in maintain-
ing neuronal function.
These  data  implicate  LC3  phosphorylation  as  a  novel 
switch  that  modulates  its  biological  function  in  mammalian 
cells. Both neuronal and nonneuronal cells exhibit endogenous 
levels of phosphorylated LC3. These observations support the 
concept of a reserve pool of phosphorylated LC3 that can be rap-
idly recruited for autophagy in response to external stimuli such 
as nutrient deprivation or mitochondrial injury. Dephosphorylation 
of LC3 would allow cells to rapidly switch from basal to induced 
autophagy, allowing the compensatory expansion of the autoph-
agic compartment that is observed after injury or stress in mam-
malian cells (Yue et al., 2009).
Materials and methods
Cell culture
293T, HeLa, and SH-SY5Y cells (American Type Culture Collection) were 
maintained in DME with 10% FBS (BioWhittaker) and 2 mM l-glutamine 
(BioWhittaker). SH-SY5Y cells were differentiated with retinoic acid 3 d 
before transfection as previously described (Plowey et al., 2008). Primary 
cortical neurons were maintained in Neurobasal (Invitrogen) supplemented 
with 2% B27 (Invitrogen) and 2 mM l-glutamine and transfected on 7 d 
in vitro. In some experiments, cells were treated with 250 µM db-cAMP 
(Sigma-Aldrich), 10 µM forskolin (Sigma-Aldrich), 10 nM FK506 (Enzo Life 
Sciences, Inc.), 10 µM H89 (EMD), 1 mM MPP
+ (1-methyl-4-phenylpyri-
dinium; Sigma-Aldrich), 250 nM okadaic acid (EMD), 2 µM rapamycin 
(LC Laboratories), or 10 µM rolipram (Sigma-Aldrich). Lipofectamine 2000   
(Invitrogen) was used to transfect the following: pcDNA 3.1(+), pcDNA-
HA-LRRK2-G2019S, pEGFP-C1, GFP-PKA, GFP-PKA-NLS, GFP-PKA–nuclear 
export signal, pEGFP-C1-LC3, GFP-RFP-LC3, and HA-LC3. Targeted PKA 
constructs were provided by S. Green (University of Iowa, Iowa City, IA). 
pEGFP-C1-LC3 and GFP-RFP-LC3 were provided by T. Yoshimori (Osaka 
autophagic neurite degeneration elicited by LRRK2 G2019S 
and MPP
+.
This study identifies a new phosphorylation site on LC3 
that reduces its recruitment and participation in autophagy. To our   
knowledge, this represents the first example of phosphorylation-
based regulation of this important autophagy effector, whose re-
cruitment represents the convergence point for several pathways   
of autophagy induction (He and Klionsky, 2009). As autophagy   
has been implicated in a growing number of human diseases, 
it has become clear that a fine balance of autophagy underlies 
healthy mammalian physiology. Phosphorylation-based regula-
tion of autophagy has thus far centered on the nutrient-sensing   
target of rapamycin–Atg1 regulatory axis, whereas loss of in-
hibitory mechanisms in the phosphoinositide 3-kinase–beclin 1 
pathway have been implicated in hereditary myopathies and 
pathological cell death (Zhu et al., 2007; Scarlatti et al., 2008; 
Vergne et al., 2009). This study implicates components of the 
ubiquitin-like lipidation system itself as a third potential point 
of autophagy down-regulation capable of suppressing autophagy 
induced by metabolic or pathological stimuli. Other autophagy 
effector proteins may also be subject to phosphoregulation, link-
ing autophagic responses to cellular injury and stress signals.
In yeast, recent studies indicate a nutrient-sensing role for 
PKA as a parallel pathway to target of rapamycin in suppressing 
autophagy, with phosphorylation of the kinase Atg1 as a conver-
gence point (Yorimitsu et al., 2007; Stephan et al., 2009). There was 
no effect on Atg1 kinase activity, but phosphorylation inhibited 
localization to the preautophagosomal structure (Budovskaya 
et al., 2005). Although a corresponding preautophagosomal 
Figure  4.  LC3 dephosphorylation is associated with enhanced recruit­
ment to autophagosomes. (a and b) Immunoblots of SH-SY5Y cells treated 
with rapamycin for 1 h (a) or MPP
+ for 24 h (b) were probed using the 
phospho-specific antibody, a C-terminal LC3 antibody (LC3), an N-terminal 
LC3 antibody (LC3-nt), and GAPDH as loading control. (c) Immunoblot-
ting of SH-SY5Y cells expressing GFP-LC3–WT or –S12A reveals that a 
greater fraction of GFP-LC3–S12A migrates as LC3-II. (d) Quantification 
of GFP-LC3 puncta in SH-SY5Y cells expressing GFP-LC3–WT or –S12A.   
*, P = 0.023 versus WT neurite; **, P = 0.014 versus WT soma; ***,   
P = 0.003 versus WT total (n = 100–115 cells/condition). Error bars in-
dicate mean ± SEM.JCB • VOLUME 190 • NUMBER 4 • 2010   538
Recombinant LC3 purification, in vitro kinase assay, and LC3  
metabolic labeling
Recombinant  GST-LC3  (pGEX-6P-1-LC3;  provided  by  M.  Shibata  and   
Y. Uchiyama, Osaka University) was induced using IPTG in DH5 bacteria 
and purified on an immobilized glutathione column (Thermo Fisher Scien-
tific) according to the manufacturer’s specifications. LC3 was cleaved from 
the GST using PreScission Protease (GE Healthcare) and incubated with 
recombinant PKA catalytic subunit (New England Biolabs, Inc.) for 2 h at 
30°C in 50 mM Tris-HCl and 10 mM MgCl2 with 200 µM ATP. Phosphory-
lation was detected by autoradiography.
For detection of LC3 phosphorylation in cells, 293T cells were trans-
fected with HA-LC3 followed by treatment with DMSO, forskolin, or for-
skolin and H89 in the presence of 1 mCi/ml 
32P as H3
32PO4. All treatments 
were in the presence of rolipram, and for the final hour of incubation, 
okadaic acid and FK506. Cells were lysed in PBS with 1% Triton X-100 
(PBST) and incubated with anti-HA antibody and agarose beads overnight 
for immunoprecipitation. After washing with PBST, proteins were eluted in 
sample buffer and separated by SDS-PAGE. Gels were silver stained, and 
HA-LC3 bands were excised. 
32P incorporation was measured as counts/
minute (LS3801; Beckman Coulter) and normalized to band intensity.
Identification of LC3 phosphorylation site by MS
Gel  bands  were  excised  and  destained,  disulfides  were  reduced  with   
TCEP (Tris(2-carboxyethyl)phosphine hydrochloride)), and sulfhydryls were 
alkylated with iodoacetamide as previously described (Shevchenko et al., 
2006). Gel plugs were digested overnight with 8 ng/µl chymotrypsin 
(Roche) at room temperature. Peptides were extracted with 1:2 (vol/vol) 
5% formic acid/acetonitrile. Samples were desalted using a ZipTip (C18; 
Millipore) and spotted for mass spectrometric analysis on a MALDI-TOF/
TOF analyzer (4800; Applied Biosystems). Peptide phosphorylation was 
detected as a gain of 80 D by MALDI-TOF-MS. Amino acid sequences 
University, Osaka, Japan). Site-directed mutagenesis of pEGFP-C1-LC3 was 
performed using QuickChange Mutagenesis II kit (Agilent Technologies).
Immunofluorescence and immunoblotting
Cells were fixed with 4% paraformaldehyde in PBS. Cells were permeabilized 
in PBS with 0.1% Triton X-100 and blocked in 2% BSA in PBS. Cells were incu-
bated with antibodies against GFP (Invitrogen), LC3 (Abgent), and/or HA tag 
(Covance) followed by the appropriate Alexa Fluor 488– or 546–conjugated 
secondary antibodies (Invitrogen). Cells were imaged in PBS at 25°C using 
a microscope (IX71; Olympus) with 20× (air) or 40× (oil) objectives with nu-
merical apertures of 0.45 or 1.30, respectively. Microsuite Five imaging soft-
ware (Olympus) was used to capture images with a camera (DP70; Olympus), 
and data were analyzed with ImageJ (National Institutes of Health) as previ-
ously described (Chu et al., 2009). Representative images display the green 
channel, which was extracted as a grayscale image using ImageJ. GFP-LC3– 
labeled AVs (puncta) were defined as bright dots >1.5 SD above the mean 
cytosolic fluorescence. For mouse cortical neurons, montages were constructed 
to capture all projecting neurites, and the total neurite length was calculated as 
the summation of all processes projecting from the cell body and all subsequent 
branches. For SH-SY5Y cells, which primarily have one major neurite project-
ing from the cell body, the longest neurite from the cell body was measured. 
The means of both these parameters are presented in graphical format.
Immunoblots were performed as previously described (Plowey et al., 
2008) with antibodies against the N terminus of LC3 (Nanotools), the   
C terminus of LC3 (Abgent), GAPDH (Abcam), lamin A/C (Cell Signaling 
Technology), or actin (Sigma-Aldrich). Phospho-specific polyclonal antibod-
ies were produced by injecting keyhole limpet hemacyanin–conjugated 
phosphopeptide  into  New  Zealand  rabbits  (Abgent).  Peptide  competi-
tion was performed to verify specificity of the phospho-specific antisera   
(Fig. S2 c). For 2D immunoblots, isoelectric focusing was performed using 
Immobiline DryStrips (GE Healthcare), pH 3–10, followed by SDS-PAGE.
Figure  5.  LC3  phosphomimic  shows  reduced  re­
cruitment  and  suppresses  neurite  degeneration.  
(a and b) SH-SY5Y cells expressing GFP-LC3–WT   
or –S12D treated with rapamycin or vehicle for 1 h. 
Quantification of GFP-LC3 puncta. *, P = 2.31 × 10
8 
versus vehicle/WT; **, P = 0.004 versus rapamycin/
WT (n = 70–80 cells/condition). (c) Quantification of 
GFP-LC3 puncta in SH-SY5Y 48 h after transfection.   
*,  P  =  0.001  versus  empty  vector/GFP-LC3–WT;   
**, P = 0.025 versus LRRK2 G2019S/GFP-LC3–WT 
(n = 100–115 cells/condition). (d) Quantification of 
GFP-LC3 puncta in SH-SY5Y cells treated with MPP
+ 
or vehicle for 48 h. *, P = 0.026 versus vehicle/WT; 
**, P = 0.043 versus MPP
+/WT (n = 85–95 cells/
condition). (e) Quantification of neurite lengths from 
SH-SY5Y cells 48 h after transfection. *, P = 6.37 × 
10
4 versus empty vector/WT; **, P = 0.008 versus 
LRRK2 G2019S/WT (n = 100–115 cells/condition). 
(f)  Quantification  of  neurite  lengths  from  SH-SY5Y   
cells treated with MPP
+ or vehicle for 48 h. *, P = 
3.58  ×  10
8  versus  vehicle/WT;  **,  P  =  3.74  ×   
10
4 versus MPP
+/WT (n = 85–95 cells/condition). 
(g and h) Quantification of neurite length and branch 
points in cortical neurons coexpressing either GFP-LC3–
WT or –S12A with empty vector or LRRK2 G2019S.   
*, P < 0.01 versus empty vector/WT; **, P < 0.036 ver-
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